Patients, dentists like OraVerse, survey shows

A majority of patients and dentists gave favorable assessments of the drug OraVerse (phentolamine mesylate), which reverses the effects of local anesthesia, according to a survey by distributor Novalar Pharmaceuticals.

The survey of 49 dentists and 370 patients showed that 86% of patients said OraVerse improved their dental experience. Some 98% of the dentists said OraVerse fills an existing need. The dentists were given 10 cartridges of OraVerse as part of the survey.

"This validates what has been known for many years: Patients do not like the loss of sensation and function caused by local anesthetics, dental professionals recognize the need for a reversal agent such as OraVerse, and both patients and dentists see the value in this solution," Novalar CEO Donna Janson said in a press release.

The survey results were presented by Richard Ghalie, M.D., chief medical officer for Novalar, at the American Association for Dental Research (AADR) annual meeting in Washington, DC.

Copyright © 2010

Page 1 of 183
Next Page